WDH: Evotec forges new drug alliance with Eli Lilly

Tuesday, 01/18/2022 08:46 from


| Views: 11

Scientists at work with a microscope and pipette (symbolic image). © Catalin Rusnac / iStock / Getty Images Plus / Getty Images

(Day of the week changed: Tuesday rpt Tuesday)

HAMBURG (dpa-AFX) – The drug researcher Evotec (Evotec share) landed a new partnership. The company wants to work together with the US pharmaceutical company Eli Lilly look for new active ingredients against metabolic and chronic kidney diseases as well as diabetes in the future. The cooperation is initially designed for three years, shared the MDax-Group on Tuesday in Hamburg. The Hanseatic League put the possible total value of the project at up to one billion US dollars.

The partner Eli Lilly is entitled to later select up to five programs from this cooperation in order to then assume responsibility for further development, clinical tests and marketing. In addition to an undisclosed upfront payment per selected program, Evotec is also eligible for up to $180 million (dollar exchange rate) of success-based milestone payments. In addition, in the event of a drug being approved, there should be staggered participation in the net sales./tav/stk/jha/


Further up?


You can obtain the base prospectus, the final terms and the key information sheets here: UH31PE,UH6G94,. Also note the further hints to this advertisement. The issuer is entitled to call open-end securities.


Subscribe to more news for free

ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Leave A Comment